{"title":"Clinical efficacy and safety of antibiotic combination therapy in the treatment of community-acquired pneumonia in children.","authors":"Huan Yang, Zhengke Xiang, Peiwei Chen","doi":"10.12669/pjms.41.4.10236","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the efficacy and safety of cefotaxime combined with azithromycin in the treatment of children with community-acquired pneumonia (CAP) and its effect on inflammatory factors.</p><p><strong>Methods: </strong>This is an observational study. A total of 118 children with CAP admitted to our hospital from June, 2022 to December, 2023 were randomly selected. According to the random number table method, they were divided into a control group and a combination treatment group, with 59 children in each group. The children in the control group were treated with azithromycin, and those in the combination treatment group were treated with cefotaxime combined with azithromycin. Both groups were treated for a week. The disappearance time of symptoms (fever, pulmonary rales, cough) and the improvement of inflammatory indicators (serum interleukin-6 (IL-6), serum C-reactive protein (CRP), and serum interleukin-8 (IL-8)) after treatment were compared. The clinical efficacy and adverse reactions were compared between the two groups.</p><p><strong>Results: </strong>The disappearance time of fever, pulmonary rales, and cough in the combination treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-6, and IL-8 in the two groups were lower than those before treatment, and the reduction in the combination treatment group was larger than that in the control group (P < 0.05). The total efficacy of the combination treatment group was significantly higher than that of the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05).</p><p><strong>Conclusion: </strong>Cefotaxime combined with azithromycin in the treatment of CAP in children can significantly improve the efficacy, quickly relieve clinical symptoms, improve the body's defense mechanism, inhibit inflammatory response, and has high safety, which is worthy of clinical promotion.</p>","PeriodicalId":19958,"journal":{"name":"Pakistan Journal of Medical Sciences","volume":"41 4","pages":"958-962"},"PeriodicalIF":1.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022586/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12669/pjms.41.4.10236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To determine the efficacy and safety of cefotaxime combined with azithromycin in the treatment of children with community-acquired pneumonia (CAP) and its effect on inflammatory factors.
Methods: This is an observational study. A total of 118 children with CAP admitted to our hospital from June, 2022 to December, 2023 were randomly selected. According to the random number table method, they were divided into a control group and a combination treatment group, with 59 children in each group. The children in the control group were treated with azithromycin, and those in the combination treatment group were treated with cefotaxime combined with azithromycin. Both groups were treated for a week. The disappearance time of symptoms (fever, pulmonary rales, cough) and the improvement of inflammatory indicators (serum interleukin-6 (IL-6), serum C-reactive protein (CRP), and serum interleukin-8 (IL-8)) after treatment were compared. The clinical efficacy and adverse reactions were compared between the two groups.
Results: The disappearance time of fever, pulmonary rales, and cough in the combination treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-6, and IL-8 in the two groups were lower than those before treatment, and the reduction in the combination treatment group was larger than that in the control group (P < 0.05). The total efficacy of the combination treatment group was significantly higher than that of the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05).
Conclusion: Cefotaxime combined with azithromycin in the treatment of CAP in children can significantly improve the efficacy, quickly relieve clinical symptoms, improve the body's defense mechanism, inhibit inflammatory response, and has high safety, which is worthy of clinical promotion.
期刊介绍：
It is a peer reviewed medical journal published regularly since 1984. It was previously known as quarterly "SPECIALIST" till December 31st 1999. It publishes original research articles, review articles, current practices, short communications & case reports. It attracts manuscripts not only from within Pakistan but also from over fifty countries from abroad.
Copies of PJMS are sent to all the import medical libraries all over Pakistan and overseas particularly in South East Asia and Asia Pacific besides WHO EMRO Region countries. Eminent members of the medical profession at home and abroad regularly contribute their write-ups, manuscripts in our publications. We pursue an independent editorial policy, which allows an opportunity to the healthcare professionals to express their views without any fear or favour. That is why many opinion makers among the medical and pharmaceutical profession use this publication to communicate their viewpoint.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
